STOCK TITAN
  1. Home
  2. News
  3. NNVC

NanoViricides Inc - NNVC STOCK NEWS

Welcome to our dedicated news page for NanoViricides (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on NanoViricides.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NanoViricides's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NanoViricides's position in the market.

News
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Rhea-AI Summary
NanoViricides, Inc. reports strong financial status with $5.31 Million cash balance and $8.07 Million in assets as of December 31, 2023. The company's lead drug candidate NV-CoV-2 shows promise in treating various viral infections. Recent clinical trials demonstrate safety and tolerability of NV-387. The Company has taken steps to improve liquidity and expand drug pipeline addressing billion-dollar markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
clinical trial covid-19
-
News
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
Rhea-AI Summary
NanoViricides, Inc. (NNVC) has developed NV-CoV-2 oral drug products containing the active pharmaceutical ingredient NV-387, demonstrating strong safety and tolerability in clinical trials. The company believes that NV-387, an ultra-broad-spectrum antiviral nanomedicine, has long-term potential against many viruses, similar to antibiotics. The technology involves copying the host-side signature used by viruses to infect hosts, enabling a direct-acting antiviral that destroys the virus. NV-387 is designed to be active against a large number of viruses, with potential market sizes reaching billions of dollars. The strong safety and tolerability of NV-387 suggests it can be used across all patients, irrespective of age, co-morbidities, or disease severity, similar to antibiotics. NanoViricides aims to revolutionize antiviral treatment with NV-387.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
clinical trial covid-19
-
News
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
Rhea-AI Summary
NanoViricides, Inc. (NNVC) successfully completed the Phase 1a/1b Clinical Trial of NV-CoV-2, reporting no adverse events. NV-387, the active ingredient, demonstrated excellent safety and broad-spectrum antiviral activity. The results indicate a promising potential for rapid response to pandemics and treatment of viral infections. The trial was managed by Karveer Meditech Pvt. Ltd. in India and conducted at Mahatma Gandhi Mission's Medical College & Hospital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
clinical trial
News
NanoViricides to Present at the Biotech Showcase in San Fransisco
Rhea-AI Summary
NanoViricides, Inc. (NNVC) to present at Biotech Showcase 2024, highlighting successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies drug products containing the novel antiviral nanomachine NV-387, with broad-spectrum antiviral activity across multiple virus families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
conferences
-
News
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
Rhea-AI Summary
NanoViricides, Inc. (NNVC) reported the successful completion of the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, a broad-spectrum antiviral drug. The drug contains the nanoviricide active agent, NV-387, which has shown strong antiviral activity against coronaviruses, RSV, and Smallpox. The Phase 1a trial in healthy volunteers was completed with no adverse events found. Recruitment for the Multiple-Ascending Dose part was also completed. NV-387 has shown broad-spectrum antiviral activity across multiple virus families, addressing an unmet medical need for a safe and effective antiviral drug. The drug has the potential to revolutionize antiviral treatment and addresses large market sizes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
earnings clinical trial
-
News
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
Rhea-AI Summary
NanoViricides, Inc. (NYSE American: NNVC) - Quarterly Report on Form 10-Q filed, Financial Status, Liquidity Improvement, Drug Pipeline, Platform Technology Expansion, and Market Potential
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
clinical trial
News
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
Rhea-AI Summary
NanoViricides, Inc. (AMEX:NNVC) reports that its broad-spectrum antiviral drug candidate, NV-387, was highly effective in an animal model for MPox and Smallpox virus infections. NV-387, currently in Phase 1a/1b human clinical trials for COVID-19 indication in India, has shown strong activity against Seasonal Coronaviruses, SARS-CoV-2, and Respiratory Syncytial Virus (RSV). The drug is designed to mimic a host cell membrane bearing 'Sulfated Proteoglycans' ('S-PG') family of virus attachment receptors, providing a broad spectrum of antiviral activity. Oral NV-387 treatment led to a significant increase in survival lifespan in animal models, indicating its relative effectiveness compared to other drugs. The company believes that NV-387 has the potential to revolutionize the fight against viruses, similar to how antibiotics revolutionized the fight against bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
clinical trial
-
News
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
Rhea-AI Summary
NanoViricides to present at PODD Conference and highlights the potential of its antiviral drug candidate NV-387
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
partnership conferences
-
News
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
Rhea-AI Summary
NanoViricides reports successful progress in Phase 1a/1b clinical trial of NV-CoV-2 antiviral drug
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
clinical trial
News
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
Rhea-AI Summary
NanoViricides, Inc. reports strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV. NV-387 is expected to advance into Phase II human clinical trials for RSV treatment, which will significantly speed up the development of the RSV drug, save costs, and improve ROI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
none
Stock NNVC logo
NanoViricides Inc

NYSE:NNVC

NNVC Rankings

#5302 Ranked by Market Cap
#3874 Ranked by Stock Gains
N/A Ranked by Dividends

NNVC Stock Data

14.72M
11.24M
4.62%
10.3%
0.84%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Shelton

About NNVC

nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir